Abstract
Hepatitis B virus asymptomatic carriers should receive treatment in certain conditions, such as prior to chemotherapy and organ transplantation. In these groups interferon alpha has limited efficacy or is even contraindicated. In contrast, lamivudine is highly effective in both preventing of and treat- ment of HBV reactivation in these immunosuppressed patients. Prevention of reactivation has better results than treating reactivation.
Keywords
Full Text
Full text is available in PDF
Copyright
© 2008, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.